# GALE

## Overview
The GALE gene encodes the enzyme UDP-galactose 4-epimerase, a member of the short-chain dehydrogenase/reductase (SDR) superfamily, which plays a pivotal role in carbohydrate metabolism. This enzyme is crucial for the Leloir pathway, facilitating the reversible conversion of UDP-galactose to UDP-glucose, thereby maintaining the balance of nucleotide sugars necessary for glycoprotein and glycolipid biosynthesis (Timson2013Comparison; Timson2005Functional). Structurally, GALE functions as a homodimer, with each monomer containing a tightly bound NAD+ molecule essential for its catalytic activity (Beerens2015UDPhexose). The enzyme's active site, located between its N-terminal and C-terminal domains, allows for the interconversion of sugar moieties, a process critical for normal cellular functions, including energy production and cell signaling (Thoden2001Human; Sakuraba2011Crystal). Mutations in the GALE gene can lead to epimerase-deficiency galactosemia, a condition with varying severity that underscores the enzyme's importance in human health (Kumar2021Molecular; Timson2005Functional).

## Structure
The human GALE protein, encoded by the GALE gene, is a homodimer, with each monomer consisting of 348 amino acids and a molecular mass of approximately 76.6 kDa (Beerens2015UDPhexose). The protein is a member of the short-chain dehydrogenase/reductase (SDR) superfamily and features signature sequences such as the YxxxK motif, crucial for catalysis, and the GxxGxxG motif, involved in nucleotide binding within the Rossmann fold (Beerens2015UDPhexose). 

The GALE enzyme's structure includes two distinct regions: the N-terminal domain, which is primarily responsible for NAD+/NADH positioning, and the C-terminal domain, which is involved in UDP-sugar binding (Thoden2001Human). The N-terminal domain features a modified Rossmann fold, characterized by a seven-strand parallel β-sheet flanked by α-helices, and contains the YXXXK motif essential for catalysis (Thoden2001Human). 

The active site of GALE is located between these domains, allowing for the interconversion of UDP-galactose and UDP-glucose, a key step in the Leloir pathway of galactose metabolism (Sakuraba2011Crystal). The enzyme's ability to bind tightly to the UMP moiety while allowing the sugar to move within the active site contributes to its structural flexibility (Timson2006The).

## Function
UDP-galactose 4-epimerase (GALE) is an enzyme encoded by the GALE gene, playing a crucial role in the Leloir pathway of galactose metabolism. In healthy human cells, GALE catalyzes the reversible interconversion of UDP-galactose and UDP-glucose, a critical step for the proper utilization of galactose and its conversion into glucose derivatives (Timson2013Comparison; Timson2005Functional). This enzymatic activity is essential for maintaining the balance of nucleotide sugars, which are vital for the biosynthesis of glycoproteins and glycolipids (Chhay2008Analysis; Broussard2020Human).

GALE functions as a homodimer, with each subunit containing a tightly bound NAD+ molecule necessary for its catalytic mechanism. The enzyme transiently oxidizes the sugar moiety at carbon-4 and then re-reduces it, allowing for the inversion of configuration (Timson2005Functional). This process is facilitated by a key tyrosine residue (Tyr157) acting as an active-site base (Timson2013Comparison).

In addition to its role in galactose metabolism, GALE is involved in the interconversion of UDP-N-acetylgalactosamine and UDP-N-acetylglucosamine, which are important for glycosylation processes (Chhay2008Analysis). Proper GALE function is crucial for preventing the accumulation of toxic metabolites and ensuring normal cellular processes, including energy production and cell signaling (Broussard2020Human; Seo2018Inherited).

## Clinical Significance
Mutations in the GALE gene, which encodes the enzyme UDP-galactose-4-epimerase, lead to epimerase-deficiency galactosemia (EDG), a rare autosomal recessive disorder. This condition manifests in three forms: peripheral, intermediate, and generalized, with varying severity based on the extent of enzyme activity reduction (Kumar2021Molecular). The generalized form is the most severe, characterized by little or no GALE activity in tissues, leading to symptoms such as restricted growth, mental development issues, cataracts, liver, kidney, and brain damage (Timson2006The; Timson2005Functional). The peripheral form shows reduced activity in blood cells but normal activity in other tissues, resulting in milder symptoms (Timson2005Functional).

Specific mutations such as p.K161N, p.R239W, and p.G302D are associated with severe phenotypes, causing significant structural and functional changes in the GALE protein, leading to decreased catalytic activity and cofactor binding (Kumar2021Molecular). The p.R51W mutation is linked to severe thrombocytopenia, affecting glycosylation processes critical for hematopoiesis and platelet biogenesis (Seo2018Inherited). These mutations can also lead to increased proteolytic sensitivity and affect the protein's overall fold, impacting its stability and function (Timson2006The).


## References


[1. (Kumar2021Molecular) S. Udhaya Kumar, Srivarshini Sankar, D. Thirumal Kumar, Salma Younes, Nadin Younes, R. Siva, C. George Priya Doss, and Hatem Zayed. Molecular dynamics, residue network analysis, and cross-correlation matrix to characterize the deleterious missense mutations in gale causing galactosemia iii. Cell Biochemistry and Biophysics, 79(2):201–219, February 2021. URL: http://dx.doi.org/10.1007/s12013-020-00960-z, doi:10.1007/s12013-020-00960-z. This article has 27 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s12013-020-00960-z)

[2. (Timson2006The) David Timson. The structural and molecular biology of type iii galactosemia. IUBMB Life (International Union of Biochemistry and Molecular Biology: Life), 58(2):83–89, February 2006. URL: http://dx.doi.org/10.1080/15216540600644846, doi:10.1080/15216540600644846. This article has 50 citations.](https://doi.org/10.1080/15216540600644846)

[3. (Broussard2020Human) Alex Broussard, Alyssa Florwick, Chelsea Desbiens, Nicole Nischan, Corrina Robertson, Ziqiang Guan, Jennifer J. Kohler, Lance Wells, and Michael Boyce. Human udp-galactose 4′-epimerase (gale) is required for cell-surface glycome structure and function. Journal of Biological Chemistry, 295(5):1225–1239, January 2020. URL: http://dx.doi.org/10.1016/s0021-9258(17)49882-6, doi:10.1016/s0021-9258(17)49882-6. This article has 19 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/s0021-9258(17)49882-6)

[4. (Thoden2001Human) James B. Thoden, Travis M. Wohlers, Judith L. Fridovich-Keil, and Hazel M. Holden. Human udp-galactose 4-epimerase. Journal of Biological Chemistry, 276(18):15131–15136, January 2001. URL: http://dx.doi.org/10.1074/jbc.m100220200, doi:10.1074/jbc.m100220200. This article has 106 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m100220200)

[5. (Seo2018Inherited) Aaron Seo, Suleyman Gulsuner, Sarah Pierce, Miri Ben-Harosh, Hanna Shalev, Tom Walsh, Tanya Krasnov, Orly Dgany, Sergei Doulatov, Hannah Tamary, Akiko Shimamura, and Mary-Claire King. Inherited thrombocytopenia associated with mutation of udp-galactose-4-epimerase (gale). Human Molecular Genetics, 28(1):133–142, September 2018. URL: http://dx.doi.org/10.1093/hmg/ddy334, doi:10.1093/hmg/ddy334. This article has 38 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/ddy334)

[6. (Sakuraba2011Crystal) Haruhiko Sakuraba, Tomoyuki Kawai, Kazunari Yoneda, and Toshihisa Ohshima. Crystal structure of udp-galactose 4-epimerase from the hyperthermophilic archaeon pyrobaculum calidifontis. Archives of Biochemistry and Biophysics, 512(2):126–134, August 2011. URL: http://dx.doi.org/10.1016/j.abb.2011.05.013, doi:10.1016/j.abb.2011.05.013. This article has 26 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.abb.2011.05.013)

[7. (Timson2005Functional) David J. Timson. Functional analysis of disease‐causing mutations in human udp‐galactose 4‐epimerase. The FEBS Journal, 272(23):6170–6177, November 2005. URL: http://dx.doi.org/10.1111/j.1742-4658.2005.05017.x, doi:10.1111/j.1742-4658.2005.05017.x. This article has 41 citations.](https://doi.org/10.1111/j.1742-4658.2005.05017.x)

[8. (Timson2013Comparison) David J. Timson and Steffen Lindert. Comparison of dynamics of wildtype and v94m human udp-galactose 4-epimerase—a computational perspective on severe epimerase-deficiency galactosemia. Gene, 526(2):318–324, September 2013. URL: http://dx.doi.org/10.1016/j.gene.2013.05.027, doi:10.1016/j.gene.2013.05.027. This article has 17 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.gene.2013.05.027)

[9. (Chhay2008Analysis) J. S. Chhay, C. A. Vargas, T. J. McCorvie, J. L. Fridovich‐Keil, and D. J. Timson. Analysis of udp‐galactose 4′‐epimerase mutations associated with the intermediate form of type iii galactosaemia. Journal of Inherited Metabolic Disease, 31(1):108–116, January 2008. URL: http://dx.doi.org/10.1007/s10545-007-0790-9, doi:10.1007/s10545-007-0790-9. This article has 26 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s10545-007-0790-9)

[10. (Beerens2015UDPhexose) Koen Beerens, Wim Soetaert, and Tom Desmet. Udp-hexose 4-epimerases: a view on structure, mechanism and substrate specificity. Carbohydrate Research, 414:8–14, September 2015. URL: http://dx.doi.org/10.1016/j.carres.2015.06.006, doi:10.1016/j.carres.2015.06.006. This article has 54 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.carres.2015.06.006)